Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SON-DP in Advanced Solid Tumors
NCT06873659Phase 1Recruiting
- Sponsor
- Qurgen
- Start
- Feb 2025
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of SON-DP in solid tumor, liver cancer and gastric cancer (GC) (8 arms), sponsored by Qurgen. Primary endpoints: Adverse Events at 7 months, Maximum Tolerable Dose at 28 days and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
SON-DP
03
Conditions
solid tumorliver cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT06873659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873659.